Skip to main content
Premium Trial:

Request an Annual Quote

Good Start Genetics, IviGen, iGenomix Ink Exclusive Reproductive Genetics Pact

NEW YORK (GenomeWeb) — Good Start Genetics, IviGen, and IviGen's parent company iGenomix today announced an exclusive partnership to offer reproductive genetics products and services to in vitro fertilization specialists and women's health professionals in the US and Canada.

The partnership enables Cambride, Mass.-based Good Start to complement its carrier screening offering with a number of genetics-based reproductive health products developed by Valenica, Spain-based IviGen and iGenomix. These include products for preimplantation genetic diagnosis and screening, products of conception testing, endometrial receptivity arrays, and sperm aneuploidy testing.

The relationship represents "a transformative step in establishing Good Start as a comprehensive, reproductive health company, serving the needs of a broad range of IVF, MFM and OBGYN physicians,” Good Start President and CEO Don Hardison said in a statement. "IviGen has rigorously developed a set of high-quality, state-of-the-art technologies already in use by leading IVF centers across the US."

David Jimenez, CEO of IviGen and iGenomix, noted that the partnership feeds into its mission "to become the leading provider of genetic testing services to the reproductive health community" and represents "a great opportunity for us to work with one of the most advanced teams in the world in relation to genetic solutions based on next-generation DNA sequencing."

Earlier this week, Good Start Genetics said that it had exclusively licensed a preimplantation genetic screening test from Johns Hopkins University.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.